Clinical Trial Update: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing Mosunetuzumab in combination with Polatuzumab Vedotin against Rituximab in combination with Gemcitabine plus Oxaliplatin in r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Mosunetuzumab (mosunetuzumab)
• OXALIPLATIN (Oxaliplatin)
• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-06